Rectal gluten challenge and diagnosis of coeliac disease.
44 patients referred consecutively for jejunal biopsy underwent rectal gluten challenge with 2 g peptic-tryptic digest (Frazer's fraction III; FF3). Rectal biopsy was done before the challenge and 6 h afterwards. Total intraepithelial lymphocytes (IEL) overlying a 10(4) micron 2 test area of muscularis mucosae were quantified by computerised image analysis. The subjects comprised 21 controls with disorders other than coeliac disease and 23 patients (14 treated, 9 untreated) with coeliac disease diagnosed by strict jejunal biopsy gold standard criteria. There was no difference between the groups in IEL numbers before challenge. Coeliac disease patients but not controls responded to FF3 with a rise in mucosal IEL (median 60.5% rise for treated, 63.0% for untreated). There was no response to challenge with beta-lactoglobulin in coeliac disease or control subjects. When a predefined, post-challenge IEL "predictive index" of more than 10% above baseline was used to indicate a diagnosis of coeliac disease, it gave a sensitivity of 90% and specificity of 91% (95% confidence intervals 78-93%). Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.
Loft
D E
DE
University Department of Medicine, Hope Hospital (University of Manchester School of Medicine), Salford, UK.
Marsh
M N
MN
Crowe
P T
PT
D002446:Celiac Disease / Q000175:diagnosis* / Q000628:therapy; D005260:Female; D005983:Glutens / Q000378:metabolism*; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism / Q000473:pathology; D007782:Lactoglobulins; D007958:Leukocyte Count; D008214:Lymphocytes; D008297:Male; D011446:Prospective Studies; D012007:Rectum / Q000378:metabolism* / Q000473:pathology
D007782:Lactoglobulins; D005983:Glutens